Not surprisingly, as soon as approaches to restore and enhance insulin signaling in the brain began to be developed, they immediately start to be tested for the treatment of AD, mild cognitive impairment and other neurodegenerative diseases. This evidence concerns the gene INS and neurodegenerative disease.